Pluristem advances towards multinational Phase III trial of PLX-PAD
Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products, today announced it intends to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture.
Click on this link for more information.
